Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Engensis in Amyotrophic Lateral Sclerosis - Extension Study
NCT05176093Phase 2Completed
- Sponsor
- Helixmith
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Engensis with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events at 365 days. Started Nov 2021; status: completed.
02
Drugs
Engensis
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05176093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05176093.